推荐产品
J Reibetanz et al.
Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 83(6), 528-535 (2012-05-16)
Adrenocortical carcinoma (ACC) is a highly aggressive endocrine disease with an incidence of 1-2 cases per million population per year. Due to the low incidence of ACC knowledge concerning the surgical management is mainly based on retrospective studies or recommendations
Adrienn Zsippai et al.
Pharmacogenomics, 13(12), 1351-1361 (2012-09-13)
The adrenolytic agent mitotane is widely used in the treatment of adrenocortical cancer; however, its mechanism of action is poorly elucidated. We have studied mitotane-induced mRNA expression changes in the NCI-H295R adrenocortical cancer cell line. Cell viability and hormone assays
S Ederhy et al.
Journal of endocrinological investigation, 35(10), 911-914 (2012-09-28)
We designed a single-center retrospective study to assess the QT interval duration and to describe cardio vascular events among patients treated with mitotane for a adrenocortical carcinoma (ACC). We selected 14 patients (6 males and 8 females) that met the
Ilse G C Hermsen et al.
European journal of endocrinology, 169(1), 51-58 (2013-04-16)
Adrenocortical carcinoma (ACC) is a rare disease with a poor prognosis and limited therapeutic options. Mitotane is considered the standard first-line therapy with only 30% of the patients showing objective tumour response. Defining predictive factors for response is therefore of
Liana Tripto-Shkolnik et al.
The Journal of clinical endocrinology and metabolism, 98(2), 443-447 (2013-01-01)
Adrenocortical carcinoma (ACC) affects patients in a broad age group, including young women. Mitotane, an adrenolytic agent, is the mainstay of treatment after surgical removal of the tumor. There is extreme paucity of information regarding the effect of mitotane on
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门